CRH Medical Corporation is poised for growth. Initially a one-product company focused on the CRH O’Regan System for hemorrhoid treatment, we’ve now expanded to servicing the gastroenterology community (one that we’ve built solid relationships with), with CRH Anesthesia Management.
Over the years, there has been a significant rise in the use of anesthesiology assisted endoscopy.
Right now, there is a large but fragmented GI anesthesia market in the U.S. and with 25 million endoscopies being performed nationwide annually, there is significant opportunity for consolidation.
CRH has established strong relationships with 2,000 GIs across the country, creating a large platform from which to leverage.
The Office of Inspector General released an opinion in 2012 indicating that GI practices who utilize anesthesia groups owned by the associated GIs and service only their practice violate self-referral laws.
Today, we’ve trained just over 1,700 of the more than 8,000 gastroenterologists in the United States – and we’re quickly training more, making this the ideal time to invest in a company poised for substantial growth.
Today, 15 million patients receive colonoscopies each year in the U.S., and around 20% are found to have hemorrhoids – creating 3 million potential recipients of the CRH O’Regan System.
With patients typically needing 2-3 treatments and CRH receiving $65 per treatment, the revenue potential is high.
CRH is covered by most insurance and much easier and less invasive than other treatment methods, meaning it’s great for patients, too.Back to topˆ